Myelodysplastic Syndrome – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Myelodysplastic Syndrome – Pipeline Review, H2 2017’, provides an overview of the Myelodysplastic Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome

The report reviews pipeline therapeutics for Myelodysplastic Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Myelodysplastic Syndrome therapeutics and enlists all their major and minor projects

The report assesses Myelodysplastic Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Acceleron Pharma Inc

Actinium Pharmaceuticals Inc

Aeglea BioTherapeutics Inc

Agios Pharmaceuticals Inc

Aileron Therapeutics Inc

AIMM Therapeutics BV

Altor BioScience Corp

Amgen Inc

Apogenix AG

Aprea AB

arGEN-X BV

Arno Therapeutics Inc

Array BioPharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Bayer AG

Bellicum Pharmaceuticals Inc

BerGenBio ASA

Bio-Path Holdings Inc

BioLineRx Ltd

BioLite Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Cantex Pharmaceuticals Inc

Celgene Corp

Cell Medica Ltd

Celldex Therapeutics Inc

Cellectis SA

Cellerant Therapeutics Inc

Celyad SA

CrystalGenomics Inc

CTI BioPharma Corp

Cyclacel Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Deciphera Pharmaceuticals LLC

Eisai Co Ltd

Eli Lilly and Co

Epizyme Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

FibroGen Inc

Forma Therapeutics Inc

Fortress Biotech Inc

Forty Seven Inc

Fujifilm Holdings Corporation

Gamida Cell Ltd

GlaxoSmithKline Plc

H3 Biomedicine Inc

Humanigen Inc

IGF Oncology LLC

Immune System Key Ltd

ImmunoGen Inc

Incyte Corp

Io Therapeutics Inc

Jazz Pharmaceuticals Plc

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Johnson & Johnson

JW Pharmaceutical Corp

Kainos Medicine Inc

Karyopharm Therapeutics Inc

Kiadis Pharma NV

Kyowa Hakko Kirin Co Ltd

La Jolla Pharmaceutical Company

Les Laboratoires Servier SAS

Lixte Biotechnology Holdings Inc

MacroGenics Inc

Madrigal Pharmaceuticals Inc.

Mateon Therapeutics Inc

medac GmbH

MediGene AG

MedImmune LLC

Medivir AB

MEI Pharma Inc

Merck & Co Inc

Merus NV

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Novartis AG

Onconova Therapeutics Inc

OncoTherapy Science Inc

Opsona Therapeutics Ltd

Pfizer Inc

Pharma Mar SA

Plexxikon Inc

Protagonist Therapeutics Inc

Rafael Pharmaceuticals Inc

Rich Pharmaceuticals Inc

Sorrento Therapeutics Inc

Stemline Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sunesis Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Takara Bio Inc

Teva Pharmaceutical Industries Ltd

Tolero Pharmaceuticals Inc

Trillium Therapeutics Inc

VasGene Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Myelodysplastic Syndrome - Overview 8

Myelodysplastic Syndrome - Therapeutics Development 9

Myelodysplastic Syndrome - Therapeutics Assessment 33

Myelodysplastic Syndrome - Companies Involved in Therapeutics Development 53

Myelodysplastic Syndrome - Drug Profiles 101

Myelodysplastic Syndrome - Dormant Projects 922

Myelodysplastic Syndrome - Discontinued Products 927

Myelodysplastic Syndrome - Product Development Milestones 928

Appendix 942

List of Tables

List of Tables

Number of Products under Development for Myelodysplastic Syndrome, H2 2017 28

Number of Products under Development by Companies, H2 2017 30

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 31

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 32

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 33

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 34

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 35

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 36

Number of Products under Development by Universities/Institutes, H2 2017 37

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 39

Products under Development by Companies, H2 2017 40

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 41

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 42

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 43

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 44

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 45

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 46

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 47

Products under Development by Companies, H2 2017 (Contd..8), H2 2017 48

Products under Development by Companies, H2 2017 (Contd..9), H2 2017 49

Products under Development by Universities/Institutes, H2 2017 50

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 51

Number of Products by Stage and Target, H2 2017 53

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 54

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 55

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 56

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 57

Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 58

Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 59

Number of Products by Stage and Mechanism of Action, H2 2017 61

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 62

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 63

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 64

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 65

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 66

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 67

Number of Products by Stage and Route of Administration, H2 2017 69

Number of Products by Stage and Molecule Type, H2 2017 71

Myelodysplastic Syndrome – Pipeline by 4SC AG, H2 2017 72

Myelodysplastic Syndrome – Pipeline by AbbVie Inc, H2 2017 73

Myelodysplastic Syndrome – Pipeline by Acceleron Pharma Inc, H2 2017 73

Myelodysplastic Syndrome – Pipeline by Actinium Pharmaceuticals Inc, H2 2017 74

Myelodysplastic Syndrome – Pipeline by Aeglea BioTherapeutics Inc, H2 2017 74

Myelodysplastic Syndrome – Pipeline by Agios Pharmaceuticals Inc, H2 2017 75

Myelodysplastic Syndrome – Pipeline by Aileron Therapeutics Inc, H2 2017 75

Myelodysplastic Syndrome – Pipeline by AIMM Therapeutics BV, H2 2017 75

Myelodysplastic Syndrome – Pipeline by Altor BioScience Corp, H2 2017 76

Myelodysplastic Syndrome – Pipeline by Amgen Inc, H2 2017 76

Myelodysplastic Syndrome – Pipeline by Apogenix AG, H2 2017 77

Myelodysplastic Syndrome – Pipeline by Aprea AB, H2 2017 77

Myelodysplastic Syndrome – Pipeline by arGEN-X BV, H2 2017 78

Myelodysplastic Syndrome – Pipeline by Arno Therapeutics Inc, H2 2017 78

Myelodysplastic Syndrome – Pipeline by Array BioPharma Inc, H2 2017 78

Myelodysplastic Syndrome – Pipeline by Astex Pharmaceuticals Inc, H2 2017 79

Myelodysplastic Syndrome – Pipeline by AstraZeneca Plc, H2 2017 79

Myelodysplastic Syndrome – Pipeline by Atara Biotherapeutics Inc, H2 2017 80

Myelodysplastic Syndrome – Pipeline by Bayer AG, H2 2017 80

Myelodysplastic Syndrome – Pipeline by Bellicum Pharmaceuticals Inc, H2 2017 81

Myelodysplastic Syndrome – Pipeline by BerGenBio ASA, H2 2017 81

Myelodysplastic Syndrome – Pipeline by Bio-Path Holdings Inc, H2 2017 82

Myelodysplastic Syndrome – Pipeline by BioLineRx Ltd, H2 2017 82

Myelodysplastic Syndrome – Pipeline by BioLite Inc, H2 2017 83

Myelodysplastic Syndrome – Pipeline by Boehringer Ingelheim GmbH, H2 2017 83

Myelodysplastic Syndrome – Pipeline by Boston Biomedical Inc, H2 2017 83

Myelodysplastic Syndrome – Pipeline by Bristol-Myers Squibb Co, H2 2017 84

Myelodysplastic Syndrome – Pipeline by Calithera Biosciences Inc, H2 2017 84

Myelodysplastic Syndrome – Pipeline by Cantex Pharmaceuticals Inc, H2 2017 85

Myelodysplastic Syndrome – Pipeline by Celgene Corp, H2 2017 85

Myelodysplastic Syndrome – Pipeline by Cell Medica Ltd, H2 2017 86

Myelodysplastic Syndrome – Pipeline by Celldex Therapeutics Inc, H2 2017 86

Myelodysplastic Syndrome – Pipeline by Cellectis SA, H2 2017 87

Myelodysplastic Syndrome – Pipeline by Cellerant Therapeutics Inc, H2 2017 87

Myelodysplastic Syndrome – Pipeline by Celyad SA, H2 2017 88

Myelodysplastic Syndrome – Pipeline by CrystalGenomics Inc, H2 2017 88

Myelodysplastic Syndrome – Pipeline by CTI BioPharma Corp, H2 2017 89

Myelodysplastic Syndrome – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017 89

Myelodysplastic Syndrome – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 90

Myelodysplastic Syndrome – Pipeline by Deciphera Pharmaceuticals LLC, H2 2017 90

Myelodysplastic Syndrome – Pipeline by Eisai Co Ltd, H2 2017 91

Myelodysplastic Syndrome – Pipeline by Eli Lilly and Co, H2 2017 91

Myelodysplastic Syndrome – Pipeline by Epizyme Inc, H2 2017 92

Myelodysplastic Syndrome – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 92

Myelodysplastic Syndrome – Pipeline by Fate Therapeutics Inc, H2 2017 93

Myelodysplastic Syndrome – Pipeline by FibroGen Inc, H2 2017 93

Myelodysplastic Syndrome – Pipeline by Forma Therapeutics Inc, H2 2017 93

Myelodysplastic Syndrome – Pipeline by Fortress Biotech Inc, H2 2017 94

Myelodysplastic Syndrome – Pipeline by Forty Seven Inc, H2 2017 94

Myelodysplastic Syndrome – Pipeline by Fujifilm Holdings Corporation, H2 2017 95

Myelodysplastic Syndrome – Pipeline by Gamida Cell Ltd, H2 2017 95

Myelodysplastic Syndrome – Pipeline by GlaxoSmithKline Plc, H2 2017 96

Myelodysplastic Syndrome – Pipeline by H3 Biomedicine Inc, H2 2017 96

Myelodysplastic Syndrome – Pipeline by Humanigen Inc, H2 2017 97

Myelodysplastic Syndrome – Pipeline by IGF Oncology LLC, H2 2017 97

Myelodysplastic Syndrome – Pipeline by Immune System Key Ltd, H2 2017 97

Myelodysplastic Syndrome – Pipeline by ImmunoGen Inc, H2 2017 98

Myelodysplastic Syndrome – Pipeline by Incyte Corp, H2 2017 98

Myelodysplastic Syndrome – Pipeline by Io Therapeutics Inc, H2 2017 99

Myelodysplastic Syndrome – Pipeline by Jazz Pharmaceuticals Plc, H2 2017 99

Myelodysplastic Syndrome – Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2017 100

Myelodysplastic Syndrome – Pipeline by Johnson & Johnson, H2 2017 100

Myelodysplastic Syndrome – Pipeline by JW Pharmaceutical Corp, H2 2017 101

Myelodysplastic Syndrome – Pipeline by Kainos Medicine Inc, H2 2017 101

Myelodysplastic Syndrome – Pipeline by Karyopharm Therapeutics Inc, H2 2017 102

Myelodysplastic Syndrome – Pipeline by Kiadis Pharma NV, H2 2017 102

Myelodysplastic Syndrome – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 103

Myelodysplastic Syndrome – Pipeline by La Jolla Pharmaceutical Company, H2 2017 103

Myelodysplastic Syndrome – Pipeline by Les Laboratoires Servier SAS, H2 2017 103

Myelodysplastic Syndrome – Pipeline by Lixte Biotechnology Holdings Inc, H2 2017 104

Myelodysplastic Syndrome – Pipeline by MacroGenics Inc, H2 2017 104

Myelodysplastic Syndrome – Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 105

Myelodysplastic Syndrome – Pipeline by Mateon Therapeutics Inc, H2 2017 105

Myelodysplastic Syndrome – Pipeline by medac GmbH, H2 2017 106

Myelodysplastic Syndrome – Pipeline by MediGene AG, H2 2017 106

Myelodysplastic Syndrome – Pipeline by MedImmune LLC, H2 2017 107

Myelodysplastic Syndrome – Pipeline by Medivir AB, H2 2017 107

Myelodysplastic Syndrome – Pipeline by MEI Pharma Inc, H2 2017 108

Myelodysplastic Syndrome – Pipeline by Merck & Co Inc, H2 2017 108

Myelodysplastic Syndrome – Pipeline by Merus NV, H2 2017 109

Myelodysplastic Syndrome – Pipeline by Millennium Pharmaceuticals Inc, H2 2017 109

Myelodysplastic Syndrome – Pipeline by Mirati Therapeutics Inc, H2 2017 109

Myelodysplastic Syndrome – Pipeline by Novartis AG, H2 2017 110

Myelodysplastic Syndrome – Pipeline by Onconova Therapeutics Inc, H2 2017 111

Myelodysplastic Syndrome – Pipeline by OncoTherapy Science Inc, H2 2017 111

Myelodysplastic Syndrome – Pipeline by Opsona Therapeutics Ltd, H2 2017 111

Myelodysplastic Syndrome – Pipeline by Pfizer Inc, H2 2017 112

Myelodysplastic Syndrome – Pipeline by Pharma Mar SA, H2 2017 112

Myelodysplastic Syndrome – Pipeline by Plexxikon Inc, H2 2017 113

Myelodysplastic Syndrome – Pipeline by Protagonist Therapeutics Inc, H2 2017 113

Myelodysplastic Syndrome – Pipeline by Rafael Pharmaceuticals Inc, H2 2017 114

Myelodysplastic Syndrome – Pipeline by Rich Pharmaceuticals Inc, H2 2017 114

Myelodysplastic Syndrome – Pipeline by Sorrento Therapeutics Inc, H2 2017 114

Myelodysplastic Syndrome – Pipeline by Stemline Therapeutics Inc, H2 2017 115

Myelodysplastic Syndrome – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 115

Myelodysplastic Syndrome – Pipeline by Sunesis Pharmaceuticals Inc, H2 2017 116

Myelodysplastic Syndrome – Pipeline by Syndax Pharmaceuticals Inc, H2 2017 116

Myelodysplastic Syndrome – Pipeline by Takara Bio Inc, H2 2017 117

Myelodysplastic Syndrome – Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017 117

Myelodysplastic Syndrome – Pipeline by Tolero Pharmaceuticals Inc, H2 2017 118

Myelodysplastic Syndrome – Pipeline by Trillium Therapeutics Inc, H2 2017 118

Myelodysplastic Syndrome – Pipeline by VasGene Therapeutics Inc, H2 2017 119

Myelodysplastic Syndrome – Dormant Projects, H2 2017 941

Myelodysplastic Syndrome – Dormant Projects, H2 2017 (Contd..1), H2 2017 942

Myelodysplastic Syndrome – Dormant Projects, H2 2017 (Contd..2), H2 2017 943

Myelodysplastic Syndrome – Dormant Projects, H2 2017 (Contd..3), H2 2017 944

Myelodysplastic Syndrome – Dormant Projects, H2 2017 (Contd..4), H2 2017 945

Myelodysplastic Syndrome – Discontinued Products, H2 2017 946

List of Figures

List of Figures

Number of Products under Development for Myelodysplastic Syndrome, H2 2017 28

Number of Products under Development by Companies, H2 2017 29

Number of Products under Development by Universities/Institutes, H2 2017 37

Number of Products by Top 10 Targets, H2 2017 52

Number of Products by Stage and Top 10 Targets, H2 2017 52

Number of Products by Top 10 Mechanism of Actions, H2 2017 60

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 60

Number of Products by Routes of Administration, H2 2017 68

Number of Products by Stage and Routes of Administration, H2 2017 68

Number of Products by Top 10 Molecule Types, H2 2017 70

Number of Products by Stage and Top 10 Molecule Types, H2 2017 70

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports